Risk and severity of COVID-19 and ABO blood group in transcatheter aortic valve patients

Study setting and patient enrollment

This study consists of a retrospective, observational investigation aimed at examining the occurrence and severity of COVID-19 in a large population of patients who undergone TAVR for severe aortic stenosis between 2010 and 2019. The study was conducted in the Strasbourg University Hospital (Strasbourg, Alsace, eastern France). The general characteristics of the study patients – including demographics, medical history, echocardiography findings, and ABO blood group – were determined from their medical records and entered into an electronic file along with follow-up data. During the COVID-19 outbreak, all patients were contacted by phone to ascertain their health status, cardiovascular and COVID-19 symptoms, medication use, and outcomes. Patient-reported data collected through a standardized questionnaire were thoroughly cross-checked with official clinical records. The study was reviewed and approved by the Institutional Review Board at the Strasbourg University Hospital (CE-2020-69). Owing to the retrospective nature of the study, the need for informed consent was waived.

Definitions

In accordance with WHO technical guidance ⁽¹⁴⁾, patients were considered as confirmed cases of COVID-19 in presence of positive reverse transcriptase-polymerase chain reaction (RT-PCR) testing of a nasopharyngeal swab specimen. Because RT-PCR can yield false-negative results, patients with typical symptoms and characteristic imaging findings on chest computed tomography (CT) were classified as confirmed cases ⁽¹⁵⁾. Patients who were hospitalized for or died of COVID-19 were considered to have severe disease.

Statistical analysis

Descriptive statistics are expressed as means ± standard deviations for continuous data or as counts (percentages) for categorical variables. Survival curves according to the ABO blood group were plotted by the Kaplan-Meier method (log-rank test) with right censoring at the time of last follow-up (May 8, 2020). The time-to-event was calculated as the time elapsed from January 1, 2020, to the date of the index event (disease onset, hospitalization, or death). Logistic regression models were constructed to evaluate the unadjusted and covariate-adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for the occurrence of COVID-19, COVID-19-related death, and severe COVID-19. Variables adjusted for in the multivariate models were those showing univariate associations at a p value <0.20. Statistical analyses were performed using SPSS, version 17.0 (IBM, Armonk, NY, USA). All tests were two-sided, and statistical significance was set as a p value of <0.05.

General characteristics

Between 2010 and 2019, a total of 1125 patients with aortic stenosis underwent TAVR in our hospital. We excluded 423 patients from the analysis due to death before January 1, 2020 (n = 403) or loss to follow-up (n = 20). Figure 1 depicts the flow of participants through the study. The general patient characteristics (n = 720; mean age: 82 ± 6.9 years; 44% men) are provided in Table 1. Common coexisting CV comorbidities included coronary artery disease (45.3%), atrial fibrillation (40.3%), congestive heart failure (35.9%), and peripheral arterial disease (27.2%). A positive history of cancer was present in 26.9% of cases, whereas chronic obstructive pulmonary disease and chronic kidney disease were identified in 11.7% and 16.5% of the study patients, respectively. At the time of interview, CV medications included angiotensin converting enzyme (ACE) inhibitors/angiotensin II receptor blockers (48.9%), statins (50.2%), anticoagulants (45.4%), and aspirin (53.3%).

• Download figure
• Open in new tab

Figure 1. Flow of patients through the study

Abbreviations: CT: Computed tomography, Covid-19: Coronavirus Disease 2019; ICU: Intensive Care Unit; RT-PCR: Reverse-Transcriptase-Polymerase-Chain-Reaction; TAVR: Transcatheter Aortic Valve Replacement.

Occurrence and presentation of COVID-19

Eighty-two patients (11.4%) had suspected COVID-19. Of them, 61 underwent RT-PCR testing and 21 chest CT. Diagnosis was confirmed in 22 cases (3.1%; 21 by RT-PCR and one on chest CT). Of them, 14 (63.6%) were hospitalized or died of COVID-19. Common clinical symptoms at presentation included dyspnea (77.3%), fever (77.3%), and cough (72.7%). Myalgia, gastrointestinal manifestations, and anosmia/ageusia occurred in 40.9%, 27.3%, and 18.2% of participants, respectively.

COVID-19, hospitalizations, and mortality

As of January 1, 2020, the all-cause and cardiovascular mortality rates in the study patients were 6.8% and 2.8%, respectively. Compared with patients without COVID-19, those with the disease had significantly higher all-cause mortality (5.6% versus 45.5%, respectively; p <0.001) and hospitalization (1.8% versus 59.1%, respectively; p <0.0001) rates (Table 2).

COVID-19 and ABO blood group

Patients with COVID-19 more frequently had the A blood group than those without (81.8% versus 41.3%, respectively). Conversely, the O (18.2% versus 46.5%, respectively), B (0% versus 9.3%, respectively), and AB (0% versus 2.9%, respectively) groups were underrepresented in patients with COVID-19. Subgroup analyses were subsequently performed according to the Rhesus (Rh) group. Interestingly, the A Rh+ blood type (68.2% versus 29%, respectively) – but not the A Rh-type (13.6 versus 12.4%, respectively) – was overrepresented in patients with COVID-19. The O Rh+ (9.1% versus 22.4%, respectively), O Rh-(4.5% versus 10.7%, respectively), B Rh+ (0% versus 7.2%, respectively), B Rh- (0% versus 2.1%, respectively), AB Rh+ (0% versus 2.5%, respectively), and AB Rh- (0% versus 1.1%, respectively) types were all underrepresented in patients with COVID-19 (Table 1). Additional analyses were also performed according to blood group A. Patients with the A blood group were more likely to develop COVID-19 compared to those with other blood types (6 versus 1%, respectively; p < 0.0001). In addition, with respect to others blood groups, patients with the A blood group presented more frequently COVID-19-related death (3.4 versus 0%, respectively; p < 0.0001) as well as the combined endpoint of COVID-19-related death or hospitalization (4 versus 0.5%, respectively; p < 0.001; Supplemental Table 1).

Predictors of COVID-19

A history of cancer and the blood type A were significant predictors of COVID-19 in univariate analysis. Multivariate analysis identified the A blood group (versus others) as the only independent predictor of COVID-19 in patients who had undergone TAVR (OR = 6.32; 95% CI = 2.11−18.92; p=0.001; Table 3). Kaplan-Meier plots of COVID-19-free survival according to the blood group (A versus others) are shown in Figure 2, panel A.

• Download figure
• Open in new tab

Figure 2.

Kaplan–Meier plots of COVID-19-free survival (panel A), COVID-19-related mortality (panel B), and severe-COVID-19-free survival (panel C) according to the ABO blood group (group A versus other groups).

Predictors of severe COVID-19

Multivariate analysis (Table 4) revealed that the blood group A (versus others; OR = 8.27; 95% CI = 1.83−37.43, p=0.006) and a history of cancer (OR = 4.99; 95% CI = 1.64−15.27, p = 0.005) were significantly and independently associated with COVID-19 severity (hospitalization and/or death). Kaplan-Meier plots of COVID-19-related mortality and severe-COVID-19-free survival are shown in Figure 2 (panels B and C, respectively).

Prevalence of COVID-19

The prevalence of COVID-19 in our patients who had undergone TAVR was 3.13%, which is higher than that observed in the general French population (24/10 000 on May 14, 2020) ⁽¹⁶⁾. Whether the increased COVID-19 rate was due to local characteristics of the outbreak in Alsace or to a higher susceptibility conferred by prior CV disease ⁽¹⁷⁾ needs further epidemiological study. Moreover, the mortality rate from COVID-19 was 45% in the current investigation. Age, frailty, and a significant burden of comorbidities are possible explanations for the high death toll ⁽¹⁸⁾. Moreover, 63.6% of our patients had severe disease (hospitalization and/or death). Despite these findings, the mechanisms by which CV disease confers susceptibility to COVID-19 remain unclear. Evidence is emerging on the association between aggressive disease and loss of ACE-2 function as a result of its proteolytic cleavage ⁽¹⁹⁾.

Under physiological conditions, ACE-2 counteracts the detrimental effects of angiotensin II ⁽²⁰⁾, which might be overexpressed in patients with CV disease ⁽²¹⁾. At sites of endothelial injury, an imbalance between ACE-2 and ACE-1 activity may result in angiotensin II accumulation – which further exacerbates tissue injury and promotes both inflammation and thrombosis ⁽²²⁾. Although our study does not address the role of ACE-2 in the susceptibility to COVID-19 among patients who had undergone TAVR, its involvement is certainly plausible.

ABO blood group and COVID-19

In the current study, patients who had undergone TAVR and had the A blood group were more prone to develop COVID-19 and were more likely to experience unfavorable outcomes. In a research conducted in 2173 Chinese patients, Zhao et al. ⁽²³⁾ showed for the first time that the A blood group was associated with an increased disease susceptibility to COVID-19 while the O group seemed less vulnerable. They also found higher death rates in patients with the A group. A more recent report from the Central Hospital of Wuhan confirmed the increased risk conferred by the A group and the reduced disease susceptibility associated with the O group ⁽¹²⁾. Another study connecting the A blood group with an increased risk of contracting COVID-19 is a research on 1599 individuals who underwent SARS-CoV-2 testing in the United States ⁽²⁴⁾. However, no relation with in-hospital mortality was found. The authors carried these observations a step further with Rh antigen testing and found that its expression could modulate the association of the ABO blood group with disease susceptibility. Similar findings were noticed in our study, albeit limited to the A group. If a subject had the A group and was also Rh+, the patient would have a substantially higher risk of COVID-19, whereas this was not the case for Rh-individuals.

Growing evidence indicates that the A blood group is associated with an increased susceptibility to and severity of COVID-19. The mechanisms beyond this association are unknown but several hypotheses might be raised. It is possible that anti-A antibodies could lead to a decreased interaction of SARS-CoV-2 with its cellular receptor ACE-2 ⁽²⁵⁾. Interestingly, the A blood group has also been related with an increased risk of CV disease ⁽²⁶⁾. Numerous biological pathways have been proposed to account for the association between the A blood group and atherothrombosis – including an increased production of soluble intercellular adhesion molecules ⁽²⁷⁾ and/or Von Willebrand factor (vWF) ⁽²⁸⁾. Other authors have emphasized the significance of vWF cleavage in subjects with the O blood group ⁽²⁹⁾ – an event which may reduce thrombotic risk in SARS-CoV-2-infected individuals ⁽¹³⁾.

Limitations

Several caveats of our investigation need to be considered. First, our study employed a retrospective design and the number of observed events (deaths and/or hospitalizations) was limited. As such, the presence of residual confounding may pose limitations in our ability to generalize our conclusions. Second, our research has an exploratory nature and we cannot rule out the presence of chance findings resulting from multiple comparisons. Another caveat is that the sex distribution of participants varied across the ABO blood groups. Specifically, men were underrepresented in the A blood group, potentially posing limitations in our ability to fully explore the impact of this variable on COVID-19 severity.

Clinical perspectives

Translational outlook

particular attention should be payed to patients who have undergone TAVR, to prevent COVID-19 and anticipate the severity of the disease. ABO group may be an additional tool for risk stratification in these patients.

Patients who have undergone TAVR are vulnerable to Covid-19